Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
Can a patient with a PMHx of pancreatic injury or disease (i.e. blunt trauma, recurrent pancreatitis) take a GLP-1 agonist safely in the setting of morbid obesity and type 2 diabetes?
Related Questions
Do you prioritize dietary modifications and exercise over early pharmacologic interventions, such as metformin or insulin, for women diagnosed with gestational diabetes?
Should we be using body fat percentage instead of BMI for determining patients' risk of metabolic syndrome?
When managing patients with suspected MASLD, what specific criteria or findings would prompt you to refer them to hepatology?
Do you use the homeostatic model assessment (HOMA) to assess for insulin resistance and change your clinical management of patients?
Are recurrent UTIs a contraindication to SGLT2i use?
What are the treatment options for severe recurrent hypoglycemia in a patient with malignant insulinoma?
Do you recommend Alpha Lipoic Acid to patients with diabetic polyneuropathy?
Do you avoid empagliflozin in patients with history of amputation?
When do you recommend screening patients with T2DM for heart failure?
Do you recommend the use of automated insulin delivery systems (such as Control IQ with Tandem insulin pumps) for managing gestational diabetes?
